TIDMRENE
RNS Number : 7937S
ReNeuron Group plc
19 March 2021
ReNeuron Group plc
("ReNeuron" or the "Company")
Exosome platform update
Further collaborations underway to demonstrate the potential of
ReNeuron's proprietary exosome platform
Emerging data shows platform's application to a range of novel
therapeutics targeting the brain and other tissues
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, provides an update on the
positive progress being made by third party commercial
collaborators with its exosome technology platform and the signing
of new collaboration agreements with a major pharmaceutical company
and leading academic institutions in the UK and mainland
Europe.
About ReNeuron's exosome technology
ReNeuron's exosome technology is being explored by
pharmaceutical, biotechnology and academic collaboration partners
as a novel delivery vehicle for third party therapeutic agents
targeting the brain and other parts of the body. The Company is
developing its lead exosome candidate from its proprietary CTX
neural stem cell line. These exosomes can be manufactured according
to GMP standards through a fully qualified, xeno-free, scalable
process and loaded with a diverse range of therapeutic agents,
including siRNA/mRNA/miRNA, CRISPR/Cas9, antibodies, peptides and
small molecules. The exosomes have been shown to exhibit a natural
ability to cross the blood brain barrier.
ReNeuron is also developing further exosome candidates derived
from a panel of additional producer cell lines owned by the
Company. These exosome candidates have the potential to broaden the
repertoire of tissues and indications that the Company is able to
target.
Further collaboration agreements
ReNeuron is exploring multiple methods of loading exosomes, both
internally and on the exosome surface, and is collaborating with
major pharmaceutical/biotechnology companies on these projects.
Since the last update in the Company's interim results statement on
24 November 2020, the Company has signed a further commercial
collaboration agreement with a major pharmaceutical company,
focusing on the potential of the Company's exosomes to deliver DNA
cargoes for expression of therapeutic genes in the brain.
A further two collaborations have also been initiated with
leading academic institutions in the UK and mainland Europe,
focusing on the delivery of CNS-targeting growth factors and siRNA
to the brain. ReNeuron has demonstrated engagement of target
receptors in the CNS by exosome-loaded growth factors during a
recent pilot study. Ongoing work in these collaborations will aim
to consolidate this finding, leading to further studies examining
functional delivery of the loaded exosomes.
Positive early pre-clinical data
Since the last update on 24 November 2020, the Company has shown
highly efficient loading of nucleic acid payloads in its exosomes
and these exosome candidates have also demonstrated functional
payload delivery, both in vitro and in vivo, to the brain and
peripheral tissues via repeat-dose intravenous administration.
Specifically, target knockdown by exosome candidates was
assessed in multiple brain regions and in key peripheral tissues
including heart, kidney and skeletal muscle. Evidence of target
knockdown was observed in each of these organs suggesting these
exosomes have the potential to deliver payloads to
therapeutically-meaningful levels to a variety of tissues. These
studies also suggest the loaded-exosomes are well-tolerated, laying
the foundation for expansion to functional delivery studies.
In addition to exploiting natural exosome tissue specificity,
ReNeuron has also now successfully decorated the surface of its
neural stem-cell derived exosomes with a specific tissue-targeting
peptide. This proprietary peptide was modified to enhance binding
to the exosome surface, resulting in a 10-fold increase in surface
binding compared with unmodified peptide. The next phase of this
collaboration aims to confirm that the peptide promotes exosome
targeting to additional tissues in vivo. This peptide platform has
the potential to generate further targeting peptides to that would
rapidly expand the therapeutic reach of ReNeuron's exosome
candidates.
Further data across these collaborations are expected during the
course of the next six months which, if positive, will enable
subsequent potential out-licensing deals with the Company's exosome
platform.
Olav Hellebø, Chief Executive Officer, commented: "Our exosome
platform is being deployed in collaboration with commercial third
parties and it is pleasing to report that these collaborations are
progressing to plan, with exciting data now emerging to demonstrate
the delivery potential of this technology with a range of novel
therapeutic agents, targeting the brain and other tissues. We look
forward to reporting further progress across these collaborations
in the months ahead."
This announcement contains inside information. The person
responsible for arranging for the release of this announcement on
behalf of the Company is Olav Hellebø, Chief Executive Officer.
ENDS
Contacts:
ReNeuron www.reneuron.com/investors
Olav Hellebø, Chief Executive Via Walbrook PR
Officer
Michael Hunt, Chief Financial Officer
Stifel Nicolaus Europe Limited (NOMAD
and Joint Broker)
Ben Maddison, Stewart Wallace +44 (0)20 7710 7600
Allenby Capital Limited (Joint Broker)
James Reeve/George Payne (Corporate
Finance)
Tim Sohal (Sales & Corporate Broking) +44 (0)20 3328 5656
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407 804
Paul McManus, Alice Woodings 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments, without the need for immunosuppressive
drugs. The Company's lead cell therapy candidate is in clinical
development for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that treat
diseases of the brain. The Company also has the ability through its
conditionally immortalised induced pluripotent stem cell (iPSC)
platform to make any tissue cells of choice; in-house programmes
are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L.
For further information visit www.reneuron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUWUURARUOAUR
(END) Dow Jones Newswires
March 19, 2021 03:00 ET (07:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024